Phage therapy in osteoarticular infections in the era of antibiotic resistance bacteria
Keywordsbacterial infection, antibiotic resistance, bacteriophage, antibiotic therapy, phage therapy
The increase in the incidence rate of multidrug resistant strains of bacteria has prompted scientists to look for alternatives to antibiotics. One option is phage therapy. The possibility of using phages (bacteriophages) in infections of almost every organ and system is being investigated. The treatment of osteoarticular infections using antibiotics is often very problematic, which is why this is an important area of interest for phage research.
As part of the bacteriophage experimental therapy conducted by Patey et al., 9 patients with osteoarticular diseases were treated. In 7 cases complete recovery was obtained. One patient achieved partial eradication of the pathogen with closure of several fistulas and stabilization of the general condition.
The study was carried out on an animal model by Yilmaz et al. showed greater effectiveness in eliminating MRSA colony forming units when combining bacteriophages with antibiotics (drop to 5000 units, no biofilm) than when using antibiotics alone (17,165 units survived, biofilm present). Independent application of phage therapy brought the worst effect (30,788 surviving units).
The results of the cited studies indicate the possible effectiveness of phage therapy in the case of osteoarticular infections. The potential synergy of antibiotics and bacteriophages in eradicating bacterial biofilm deserves attention.
O. Patey, S. McCallin, H. Mazure, M. Liddle, A. Smithyman, and A. Dublanchet, “Clinical indications and compassionate use of phage therapy: Personal experience and literature review with a focus on osteoarticular infections,” Viruses, vol. 11, no. 1, Jan. 2019.
D. Myelnikov, “An Alternative Cure: The Adoption and Survival of Bacteriophage Therapy in the USSR, 1922–1955,” J. Hist. Med. Allied Sci., vol. 73, no. 4, p. 385, 2018.
V. La Fauci and V. Alessi, “Antibiotic resistance: Where are we going?,” Ann. di Ig., vol. 30, no. 4, pp. 52–57, 2018.
D. M. Lin, B. Koskella, and H. C. Lin, “Phage therapy: An alternative to antibiotics in the age of multi-drug resistance,” World J. Gastrointest. Pharmacol. Ther., vol. 8, no. 3, p. 162, 2017.
C. Yilmaz, M. Colak, B. C. Yilmaz, G. Ersoz, M. Kutateladze, and M. Gozlugol, “Bacteriophage therapy in implant-related infections: An experimental study,” J. Bone Jt. Surg. - Ser. A, vol. 95, no. 2, pp. 117–125, Jan. 2013.
B. Koskella and S. Meaden, “Understanding Bacteriophage Specificity in Natural Microbial Communities,” Viruses, vol. 5, no. 3, pp. 806–823, Mar. 2013.
M. G. Weinbauer, “Ecology of prokaryotic viruses,” FEMS Microbiology Reviews, vol. 28, no. 2. Oxford Academic, pp. 127–181, 01-May-2004.
L. Zhang et al., “Intracellular Staphylococcus aureus control by virulent bacteriophages within MAC-T bovine mammary epithelial cells,” Antimicrob. Agents Chemother., vol. 61, no. 2, Feb. 2017.
S. A. Sarker et al., “Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh,” EBioMedicine, vol. 4, pp. 124–137, Feb. 2016.
P. Leszczyński, B. Weber-Da̧browska, M. Kohutnicka, M. Łuczak, A. Górecki, and A. Górski, “Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker - Case report,” Folia Microbiol. (Praha)., vol. 51, no. 3, pp. 236–238, May 2006.
E. Jończyk-Matysiak et al., “Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes,” Front. Microbiol., vol. 8, p. 164, Feb. 2017.
V. V. Morozova, Y. N. Kozlova, D. A. Ganichev, and N. V. Tikunova, “Bacteriophage treatment of infected diabetic foot ulcers,” in Methods in Molecular Biology, vol. 1693, Humana Press Inc., 2018, pp. 151–158.
P. Jault et al., “Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial,” Lancet Infect. Dis., vol. 19, no. 1, pp. 35–45, Jan. 2019.
T. Rose et al., “Experimental phage therapy of burn wound infection: difficult first steps.,” Int. J. Burns Trauma, vol. 4, no. 2, pp. 66–73, 2014.
P. Speck and A. Smithyman, “Safety and efficacy of phage therapy via the intravenous route,” FEMS Microbiol. Lett., vol. 363, no. 3, Feb. 2016.
R. T. Schooley et al., “Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection,” Antimicrob. Agents Chemother., vol. 61, no. 10, Oct. 2017.
L. Leitner et al., “Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomized, placebo-controlled, double-blind clinical trial,” BMC Urol., vol. 17, no. 1, pp. 1–6, Sep. 2017.
L. D. R. Melo et al., “Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections,” Front. Microbiol., vol. 7, no. JUN, p. 1024, 2016.
G. Zhang et al., “Bacteriophage effectively kills multidrug resistant Staphylococcus aureus clinical isolates from chronic rhinosinusitis patients,” Int. Forum Allergy Rhinol., vol. 8, no. 3, pp. 406–414, Mar. 2018.
S. A. Fong et al., “Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients,” Front. Cell. Infect. Microbiol., vol. 7, no. SEP, p. 418, Sep. 2017.
A. Malik, Z. Mohammad, and J. Ahmad, “The diabetic foot infections: Biofilms and antimicrobial resistance,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 7, no. 2, pp. 101–107, Apr. 2013.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 145
Number of citations: 0